Functional Trunk Training in Ataxia Patients
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04740359 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 5, 2021
Last Update Posted : February 5, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ataxia, Spinocerebellar Ataxias, Hereditary | Other: Functional training Other: Routine training | Not Applicable |
Hereditary ataxias are a group of genetic diseases characterized by slow progressive gait disturbance. In addition, coordination disorders can be seen in extremities, speech and eye movements. Atrophy is common in the cerebellum. Friedreich's ataxia, ataxia telangiectasia, ataxia with vitamin E deficiency, infantile-onset spinocerebellar atrophy and Marinesco-Sjögren syndrome are autosomal recessive hereditary ataxias. The constant main sign of autosomal recessive ataxia is progressive ataxia.
The trunk has an important role on dynamic stabilization for postural reactions and limb movements. A good trunk support enables movements in other parts of the body to occur more regularly. Trunk stabilization is important to support upper and lower extremity movements, to meet the loads, and to protect the spinal cord. The relationship between upper extremity function, daily living activities and trunk functions has been emphasized in many studies but comparative studies about the rehabilitation were very less.
This study is to evaluate the effect o functional trunk training in patients with autosomal recessive ataxia.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Participants were divided in two groups. Two groups will get two different intervention. |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | The Effect of Functional Trunk Training on Trunk Control and Upper Extremity Functions in Hereditary Ataxia Patients With Autosomal Recessive |
| Actual Study Start Date : | January 12, 2021 |
| Estimated Primary Completion Date : | January 12, 2022 |
| Estimated Study Completion Date : | January 30, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Control
Routine training; mat exercises and perturbation training
|
Other: Routine training
The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The strengthening exercises were applied on the mat (3x10 for the first 4 weeks and 3x15 repetition for the last 4 weeks). Eyes open-closed perturbation training was performed for trunk control in sitting and standing positions (10 min.). |
|
Experimental: Study
Trunk training; Functional training, mat exercises and perturbation training
|
Other: Functional training
The therapy program was planned for 8 weeks and the sessions were performed in 45 minutes (min) for 3 days a week. The functional reach (forward-lateral-cross), trunk rotation exercises were performed in the sitting positions.(25min) Facilitation of trunk extension and elongation in the prone position (10 min). Thoracic mobilization on exercise ball (10min). |
- The Functional Independence [ Time Frame: through of te study, average 8 weeks ]The Functional Independence Scale for Children (WeeFIM) was used determine to independence level.
- Trunk impairment [ Time Frame: through of te study, average 8 weeks ]The Trunk Disorder Scale (TIS) was used to assess static and dynamic sitting balance and trunk coordination
- The severity of ataxia [ Time Frame: through of te study, average 8 weeks ]The International Ataxia Rating Scale (ICARS) was used to determine the severity
- The quality of life [ Time Frame: through of te study, average 8 weeks ]The Children's Quality of Life Scale (PedsQL) was used determine to quality of life level.
- Upper extremity functional performance [ Time Frame: through of te study, average 8 weeks ]The 9-Hole Peg test was used to evaluate upper extremity performance
- Functional Reach Test [ Time Frame: through of te study, average 8 weeks ]Functional Reach Test was used determine to dynamic trunk balance
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Without any communication impairment (seeing, hearing, hearing),
- Have not had surgery for the upper and lower extremities in the last 6 months,
- Between the ages of 5 and 18,
- The mental level determined by the pediatrician is sufficient,
Exclusion Criteria:
- Patients who want to leave the study at any stage of the study
- Patients who do not attend regular training
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04740359
| Turkey | |
| Hasan kalyoncu üniversitesi | |
| Gaziantep, Eyalet/Yerleşke, Turkey, 27100 | |
| Responsible Party: | Sedat Yiğit, Res Asst, Hasan Kalyoncu University |
| ClinicalTrials.gov Identifier: | NCT04740359 |
| Other Study ID Numbers: |
2020/107 |
| First Posted: | February 5, 2021 Key Record Dates |
| Last Update Posted: | February 5, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
ataxia,rehabilitation,trunk,disabilities |
|
Ataxia Cerebellar Ataxia Spinocerebellar Ataxias Spinocerebellar Degenerations Dyskinesias Neurologic Manifestations Nervous System Diseases |
Cerebellar Diseases Brain Diseases Central Nervous System Diseases Spinal Cord Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn |

